Ketamine for Anxiety: FDA Status, Clinical Evidence, and Safety Concerns

Quick answer: Ketamine is an anesthetic and dissociative drug being studied off-label for severe treatment-resistant anxiety. It is NOT FDA-approved for any anxiety disorder (Spravato, the only FDA-approved ketamine product, is approved only for treatment-resistant depression). Emerging but small studies suggest rapid short-term reduction of anxiety symptoms in severely ill patients, but effects are not durable without repeat sessions, and the evidence is preliminary. Ketamine for anxiety should only be administered in medically-supervised clinical settings under a licensed psychiatrist. Do NOT use ketamine at home unsupervised. Unregulated "ketamine clinics" and telehealth providers have caused documented deaths and serious harm. Dissociation can be traumatic. Addiction and Schedule III controlled substance status mean abuse potential is real.

If you are in crisis, call 988 (US Suicide and Crisis Lifeline) or text HOME to 741741 (Crisis Text Line).

WARNING: CRITICAL SAFETY DISCLAIMER

This section is placed near the top because ketamine carries severe risks, especially outside regulated settings.

FDA Status

Ketamine is NOT FDA-approved for any anxiety disorder. Period.
Spravato (esketamine) nasal spray is the ONLY FDA-approved ketamine product, approved 2019 for treatment-resistant depression and 2020 for major depressive disorder with suicidal ideation. It requires mandatory REMS (Risk Evaluation and Mitigation Strategy) program: in-clinic administration, vital sign monitoring, same-day discharge.
All ketamine use for anxiety is off-label. Off-label means a clinician prescribes it outside its approved indication. Off-label prescribing is legal, but it does not mean the drug is proven safe or effective for that use.

Ketamine is a Schedule III Controlled Substance

Ketamine is classified by the DEA as Schedule III: known abuse and addiction potential.
Recreational ketamine use is illegal and carries addiction risks, documented cases of dependency, and bladder toxicity with chronic misuse (urinary frequency, ulcerative cystitis, chronic pain).
Supervised clinical ketamine for anxiety is different from street use, BUT the drug itself carries inherent addiction risk and should only be administered by a licensed prescriber in a monitored clinical setting.

Unregulated Ketamine Clinics and Telehealth: Documented Harms

FDA consumer warnings (2023-2024): FDA warned the public about unregulated ketamine clinics operating outside proper medical oversight.
Matthew Perry death (2023): Actor's death linked to unmonitored ketamine from telehealth providers.
Multiple reported deaths and serious injuries: Inadequate screening for contraindications, unsupervised dissociation experiences, at-home lozenges without medical oversight, drug interactions not checked.
DEA crackdown: DEA has taken enforcement action against telehealth companies prescribing ketamine without proper evaluation, monitoring, or prescription writing standards.
At-home lozenges flagged: Sublingual ketamine lozenges increasingly used via telehealth without in-clinic supervision. Dissociation cannot be managed. Medical emergencies (cardiovascular, psychiatric) cannot be addressed.

Who Should NOT Use Ketamine

Active psychosis or psychotic disorders (ketamine can worsen)
Active mania or bipolar I disorder (dissociative effects can be destabilizing)
Severe cardiovascular disease, uncontrolled hypertension (ketamine raises BP/HR acutely)
Pregnancy (contraindicated; reproductive effects unknown)
Prior substance use disorder history (relative contraindication; addiction risk higher)
Unwillingness or inability to participate in integration therapy
Unstable housing or inability to follow up post-session

Core Risks of Ketamine Use

Dissociation: Out-of-body experiences, altered perception, time distortion, depersonalization. Without preparation and integration, can be terrifying and traumatic.
Cardiovascular: Transient elevation of blood pressure and heart rate during infusion. Must monitor. Contraindicated in severe HTN or cardiac disease.
Addiction potential: Schedule III. Cases of dependency when used repeatedly unsupervised.
Bladder and urinary toxicity: Chronic misuse can cause ulcerative cystitis, frequency, pain. Rare with supervised therapy, but possible.
Drug interactions: Benzodiazepines blunt ketamine's effect. Other CNS depressants increase risk.
Worsening mood: Some patients report increased depression or suicidal ideation post-session.
Psychological trauma: Dissociative experience can be so intense/disorienting that without proper support and integration, it causes harm rather than healing.

Bottom Line on Unregulated Use

Do not seek ketamine treatment from:

Unregulated "ketamine wellness clinics" without proper medical oversight
Telehealth providers prescribing at-home lozenges without medical screening or monitoring
Providers who do not screen for contraindications (cardiovascular, psychiatric history, pregnancy)
Providers who do not monitor vital signs during administration
Providers who do not offer integration therapy post-session

What is ketamine?

Ketamine is a dissociative anesthetic developed in the 1970s. It is used clinically in anesthesia, acute pain management (especially in emergency medicine and surgical settings), and pediatric sedation. It works as an NMDA (N-methyl-D-aspartate) receptor antagonist, blocking glutamate signaling in the brain.

Outside of approved medical uses, ketamine is a recreational drug with abuse potential. It is also called "K," "Special K," "Vitamin K," or "Ket." Recreational ketamine use is illegal without prescription and carries addiction, bladder toxicity, and psychological risks.

In recent years, academic research has explored whether ketamine's rapid effects on mood and anxiety might be harnessed therapeutically. This has led to a proliferation of unregulated "ketamine clinics" offering off-label treatments for depression, anxiety, and chronic pain, often with inadequate medical oversight. This is the context in which ketamine for anxiety is discussed here.

How ketamine might work for anxiety (mechanism, theoretical)

Ketamine blocks NMDA receptors, which changes glutamate signaling in the prefrontal cortex and other brain regions. The proposed mechanism for rapid mood/anxiety reduction involves:

Rapid glutamate surge and downstream effects: Ketamine-induced NMDA blockade triggers an acute surge of glutamate, which then activates AMPA receptors. This paradoxical increase in excitatory signaling is theorized to promote rapid synaptogenesis (formation of new synaptic connections) in the prefrontal cortex, a region involved in emotion regulation and fear extinction.
BDNF upregulation: Ketamine increases brain-derived neurotrophic factor (BDNF), a protein that supports neuroplasticity and growth of new neurons, especially in the hippocampus and prefrontal cortex. Increased BDNF is associated with improved mood and fear processing.
MTOR pathway activation: Ketamine activates the mTOR pathway, which promotes protein synthesis and synaptogenesis, reversing some of the neurobiological changes associated with depression and anxiety.
Different timeline than SSRIs: SSRIs (selective serotonin reuptake inhibitors, the standard first-line treatment for anxiety) take 2-4 weeks to work because they require downstream neuroadaptation. Ketamine's effects can emerge within hours to days, suggesting a fundamentally different mechanism.

This is compelling preclinically. However, the translation to humans is preliminary, especially for anxiety. Most research has focused on depression. The specific mechanisms in anxiety remain largely theoretical.

FDA approvals and regulatory status

Spravato (esketamine) nasal spray

FDA approval: 2019 for treatment-resistant depression (TRD). 2020 for major depressive disorder (MDD) with suicidal ideation.
REMS program: Spravato requires enrollment in a Risk Evaluation and Mitigation Strategy. Patients must:
Be screened for contraindications (cardiovascular disease, psychosis, etc.)
Receive the medication in a certified healthcare clinic, not at home
Have vital signs monitored during and after administration
Remain under observation for at least 2 hours post-dose
Have a healthcare provider present
Enroll in a patient registry
NOT approved for anxiety: Spravato's approval is ONLY for depression, not anxiety.
Cost and access: Often covered by insurance for approved indications (TRD, MDD with SI), but coverage varies. Out-of-pocket cost can range $800-2,000+ per treatment.

Racemic ketamine (intravenous or intramuscular)

NOT FDA-approved for any psychiatric indication: Not approved for depression, anxiety, or any mental health disorder.
Legal for off-label prescribing: Clinicians can prescribe it off-label. However, off-label does not mean safe or effective. Off-label prescribing is common but requires informed consent and appropriate monitoring.
APA 2017 Consensus Statement: The American Psychiatric Association issued guidance on ketamine administration for mood disorders, recommending:
Use only in research settings or specialty clinics with expertise
Screening for contraindications
Vital sign monitoring during and after infusion
Integration therapy post-session
Informed consent about off-label status and preliminary evidence
Typical administration: IV infusion of 0.5-1.0 mg/kg over 40-60 minutes, often in a series of 6 sessions over 2-3 weeks, then maintenance sessions as needed.
Cost: No insurance coverage typical for off-label use. Out-of-pocket: typically $2,500 to $6,000+ for a 6-session course.

Evidence for ketamine for anxiety: Honest assessment

The evidence for ketamine for anxiety is emerging and preliminary. Most published research is on depression or specific treatment-resistant anxiety cases. Here is what the literature shows:

Published evidence (anxiety-specific):

Glue et al. 2017: Open-label trial of IV ketamine for generalized anxiety disorder. Small sample. Found rapid reduction in anxiety scores within days. Effects were not durable without repeat dosing. Highly preliminary.
Glue et al. 2020: Follow-up study on ketamine for GAD and social anxiety. Again, small sample, open-label design (not blinded), short-term benefit. No head-to-head comparison with SSRIs.
Taylor et al. 2018: Case series on ketamine for social anxiety disorder. Promising short-term effects. Again, not a randomized controlled trial.
Schoevers et al. 2016: Study of treatment-resistant anxious depression (anxiety + depression together). IV ketamine showed benefit in severely ill patients. But anxiety was not the sole target; depression was primary.
Ionescu et al. 2019: IV ketamine for severe treatment-resistant anxiety in a specialized research setting. Rapid response in heavily pre-treated patients. Very small sample; not generalizable to mild or moderate anxiety.

Limitations of the evidence:

Small samples: Most studies include 10-30 participants, not hundreds.
Open-label designs: Not blinded; risk of placebo effect or observer bias.
Short-term benefit: Effects observed over days to weeks. Long-term durability unknown. Most patients relapse or plateau within days-weeks without repeat dosing.
Dose-response not established for anxiety: Studies use varying doses and intervals. No consensus on optimal dose, frequency, or duration for anxiety specifically.
No head-to-head with SSRIs: No RCT comparing ketamine to an SSRI or CBT in anxiety disorder patients. We do not know if ketamine is superior, equivalent, or inferior to first-line treatments.
Heterogeneous populations: Some studies mix GAD, social anxiety, treatment-resistant depression with anxiety features. Anxiety is not one condition; these treatments may work differently for different types.

What this means:

Ketamine shows promise for severe, treatment-resistant anxiety in very ill patients in a specialized research setting. It is not an established or mainstream treatment. It is not first or second-line. It is not a substitute for evidence-based therapies (CBT, EMDR, exposure) or well-established medications (SSRIs, SNRIs).

Who might be considered for ketamine for anxiety?

Potential candidates (NOT a recommendation; only a psychiatrist can decide):

Severe generalized anxiety disorder or social anxiety disorder
Failed adequate trials of 2 or more SSRIs/SNRIs at therapeutic dose for 8+ weeks each
Failed comprehensive CBT and/or exposure therapy with a trained therapist
Significant functional impairment (unable to work, attend school, socialize)
High suicide risk related to anxiety (rare, but possible)
Access to a specialized, reputation clinic with experienced psychiatrist

Realistic context: Most severely anxious patients benefit from optimized SSRI dosing, longer-term CBT, or newer therapies like ketamine's use is reserved for treatment-resistant cases in research or specialty settings.

How ketamine is administered in clinical settings

Intravenous (IV) infusion

Dose: Typically 0.5 mg/kg to 1.0 mg/kg
Duration: 40-60 minute infusion
Setting: Outpatient clinic, medical office, or research setting with IV capability
Monitoring: Vital signs (BP, HR, O2 sat, EKG) before, during, and after
Observation: Typically 2 hours post-infusion before discharge
Frequency: Often 6 sessions over 2-3 weeks, then maintenance sessions weekly to monthly
Experience: Onset of dissociation within 10-15 minutes, peaks mid-infusion, subsides within 1-2 hours post-end

Intranasal (Spravato/esketamine)

Dose: 54 mg, 78 mg delivered via nasal spray
Setting: Certified healthcare clinic (REMS requirement)
Monitoring: Vital signs, healthcare provider present, 2-hour observation minimum
Frequency: Twice weekly for 4 weeks, then weekly for 4 weeks, then monthly maintenance
Experience: Dissociation within minutes, peaks ~10-15 min, subsides within 1-2 hours

Sublingual/lozenges (at-home, telehealth)

Dose: Usually 100-300 mg lozenges
Setting: Home (unsupervised) or clinic
Monitoring: Often minimal or none
Risk: HIGH. Dissociation cannot be managed at home. No emergency support. Drug interactions not checked. Cardiovascular effects not monitored. This is the format flagged by FDA and DEA.

Intramuscular (IM)

Dose: 0.5-1.0 mg/kg
Setting: Clinic
Monitoring: Vital signs, observation
Frequency: Usually less common than IV; similar regimen
Advantage: Easier than IV (no IV line needed)

The dissociative experience: what to expect

During infusion/administration

Onset: Dissociation usually begins 10-15 minutes into IV infusion
Peak: Usually 20-40 minutes into infusion, mid-session
Subjective experience: Out-of-body feeling, altered perception, time distortion, floating, dream-like state, visual distortions, sense of being separate from body
Intensity: Varies widely. Some describe it as peaceful or visionary. Others find it frightening or disorienting.
Physical sensations: Dizziness, tingling, tremor, slow/heavy limbs, dissociation from pain
Duration: Usually subsides within 1-2 hours after infusion ends
Recovery: Most people are clear-headed and safe to discharge within 2 hours (requires escort home)

Post-session (integration)

Integration therapy is strongly recommended. This is a guided conversation with a therapist or psychiatrist to:
Process the dissociative experience
Translate insights from altered state into psychological meaning
Assess for trauma responses
Plan follow-up care
Without integration, the dissociative experience can feel meaningless or traumatic.

Side effects and risks

Common side effects during/after infusion

Dissociation (see above)
Nausea (mild to moderate)
Dizziness
Blurred vision
Transient increase in blood pressure (usually mild, self-resolving)
Transient increase in heart rate (usually mild, self-resolving)
Mild euphoria or mood elevation
Anxiety (paradoxically, some people feel more anxious during the session, then better afterward)

Serious risks

Cardiovascular: Elevation of BP and HR during infusion. Contraindicated in uncontrolled hypertension, acute coronary syndrome, or severe cardiac arrhythmias. Risk of myocardial infarction in susceptible patients.
Psychological/psychiatric: Dissociative experiences can be traumatic if not properly prepared for or integrated. Risk of worsening depression or suicidal ideation post-session (rare but documented). Risk of depersonalization/derealization persisting after session.
Addiction and dependence: Schedule III substance. Cases of psychological and physical dependence when used repeatedly unsupervised. Less common with supervised clinical ketamine, but possible.
Bladder toxicity: Chronic unsupervised or high-dose ketamine use can cause chemical cystitis, urinary frequency, dysuria, and chronic pain. Rare with supervised therapy, but risk increases with repeated sessions over months-years.
Psychosis: Ketamine can precipitate psychotic episodes in susceptible individuals (undiagnosed bipolar disorder, schizophrenia spectrum). Screening essential.
Interactions: Benzodiazepines blunt ketamine's effect. Other CNS depressants (alcohol, opioids, barbiturates) increase risk of respiratory depression, oversedation, overdose.

Risks of unregulated clinics and telehealth: Detailed

Documented harms

Inadequate screening: Patients with contraindications (psychosis, severe HTN, cardiac disease, pregnancy, active substance use disorder) not identified before treatment.
Unsupervised dissociation: At-home lozenges mean dissociative crises cannot be managed in real time. Patients may hurt themselves, have accidents, or experience trauma.
No integration support: Many telehealth providers do not offer integration therapy, leaving patients confused, retraumatized, or without psychological support.
Inadequate monitoring: Vital signs not monitored; cardiovascular emergencies not recognized.
Deaths reported: Matthew Perry (2023) and others have died from complications related to unsupervised ketamine, including overdose, interaction with other drugs, or acute psychiatric crises.
No drug interaction screening: Clinicians may not have full medication list, leading to dangerous interactions.
Inappropriate patient selection: Patients with depression and suicidal ideation offered ketamine without safety planning or inpatient monitoring.

FDA and DEA response

FDA issued consumer alert 2023-2024 warning about unregulated ketamine clinics and at-home telehealth.
DEA has taken enforcement action against multiple telehealth companies for unlicensed ketamine prescribing.
No federal approval for at-home ketamine lozenges; only Spravato (in-clinic only) has regulatory pathway.

Cost and access

Supervised clinical ketamine (IV, IM, in-clinic intranasal)

Typical cost: $2,500 to $6,000+ out-of-pocket for a 6-session course (induction phase). Additional maintenance sessions $500-1,000 each.
Insurance coverage: Rare. Most insurance does not cover off-label ketamine for anxiety. May cover Spravato for approved depression indication, but coverage varies.
Access: Limited to specialized clinics in major cities. Rural access difficult.

Spravato (esketamine, in-clinic)

Typical cost: $800-2,000+ per treatment (induction) through insurance or out-of-pocket.
Insurance coverage: Often covered for treatment-resistant depression (FDA-approved indication). Coverage for depression with suicidal ideation also common.
Access: More clinics offering Spravato than IV ketamine because of FDA approval pathway and standardized REMS program.

At-home telehealth lozenges

Cost: Often cheap ($400-800 for 6-session course), marketed as "affordable."
Insurance: Not covered.
Hidden costs: Lack of integration therapy, risk of adverse events, potential need for emergency care post-dissociation.

Alternatives before considering ketamine

Before pursuing ketamine for anxiety, clinicians typically recommend:

Optimize SSRI/SNRI: Ensure adequate trial (therapeutic dose for 8+ weeks). Consider switching to a different SSRI if first did not work.
Comprehensive CBT or exposure therapy: Cognitive behavioral therapy and exposure-based treatments are first-line and have the strongest evidence for anxiety. See a psychologist specializing in anxiety disorders.
EMDR: Eye Movement Desensitization and Reprocessing can be effective for anxiety rooted in trauma.
DBT: Dialectical Behavior Therapy useful for anxiety + emotion dysregulation.
Evaluate for treatment-resistant diagnosis: Is the anxiety truly treatment-resistant, or has the patient not received adequate CBT or medication trial?
TMS (Transcranial Magnetic Stimulation): Non-invasive brain stimulation, FDA-approved for depression; emerging evidence for anxiety. Less invasive than ketamine.
Medication optimization: Consider augmentation strategies (adding buspirone, second-generation antipsychotic at low dose, prazosin, etc.) under psychiatrist supervision.
Address comorbidities: Sleep, substance use, medical conditions (thyroid, cardiopulmonary) that can worsen anxiety.

Ketamine should be considered only after these have been attempted or explicitly deemed not suitable by a psychiatrist.

Bottom line

Ketamine is NOT a first or second-line treatment for anxiety. It is a novel treatment being researched for SEVERE, TREATMENT-RESISTANT anxiety in specialized clinical settings. It is not FDA-approved for any anxiety disorder. The evidence is preliminary. Serious risks include dissociation (which can be traumatic), addiction potential, cardiovascular effects, bladder toxicity with chronic use, and psychological harm.

Unregulated ketamine clinics and telehealth providers are a major safety concern. Multiple deaths and serious injuries have been reported. Do not seek treatment outside a reputable, supervised medical clinic.

If you have severe anxiety despite adequate trials of standard treatments, ask your psychiatrist about ketamine in a research setting or specialty clinic—not a commercial telehealth company.

FAQ

Is ketamine FDA-approved for anxiety?

No. Ketamine is not FDA-approved for any anxiety disorder. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression only, not anxiety. All ketamine use for anxiety is off-label, meaning clinicians prescribe it outside its approved indication. Off-label prescribing is legal but does not mean the drug is proven safe or effective for anxiety.

Is ketamine safe for anxiety?

Ketamine carries significant risks: dissociation (which can be traumatic), cardiovascular effects (elevated BP/HR), addiction potential (Schedule III controlled substance), bladder toxicity with chronic use, and risk of worsening mood or suicidal ideation in some patients. Serious risks are higher in unregulated settings. In a properly supervised medical clinic with screening, monitoring, and integration support, risks are lower but still present. Ketamine is not "safe" in the way that well-established SSRIs or CBT are; it is a specialized treatment for severe, treatment-resistant cases only.

Is at-home ketamine safe?

No. The FDA and DEA have warned against at-home ketamine use and unregulated telehealth providers. At-home lozenges are not monitored; dissociative crises cannot be managed; cardiovascular emergencies cannot be recognized; integration therapy is absent. Multiple deaths have been reported. Do not use at-home ketamine, regardless of cost or convenience.

How fast does ketamine work for anxiety?

Some reports suggest anxiety reduction within hours to days of a ketamine infusion. This is much faster than SSRIs (which take 2-4 weeks). However, effects are typically short-term (days to weeks) and require repeat dosing for sustained benefit. Ketamine is not a one-time cure; it requires a series of sessions (typically 6+ initially) followed by maintenance sessions.

Will ketamine cure my anxiety?

No. Ketamine is not a cure. It is a short-term tool that may reduce anxiety symptoms in some people, especially those with severe, treatment-resistant anxiety. Most people need repeat sessions. Effects wear off without maintenance dosing. Ketamine is not a substitute for therapy or foundational treatment like CBT, which can provide lasting change.

Can I get addicted to ketamine therapy?

Yes, there is a risk. Ketamine is a Schedule III controlled substance with known addiction potential. While addiction risk is lower with supervised clinical use (typically once or twice weekly), psychological and physical dependence can develop with repeated use, especially if doses increase or frequency increases without clinical oversight. This is another reason ketamine should only be used in supervised clinical settings with clear protocols and limits.

What is Spravato, and is it the same as regular ketamine?

Spravato (esketamine) is the only FDA-approved ketamine product. It is a nasal spray of esketamine (the active S-enantiomer of ketamine), approved for treatment-resistant depression and MDD with suicidal ideation. Spravato must be administered in a certified clinic with REMS oversight: vital sign monitoring, 2-hour observation, healthcare provider present. It costs more than off-label IV ketamine but comes with FDA approval and regulatory safeguards. Spravato is NOT approved for anxiety.

How much does ketamine therapy cost?

Off-label IV/IM ketamine: typically $2,500-6,000+ out-of-pocket for a 6-session induction course. Maintenance sessions $500-1,000 each. Insurance rarely covers. Spravato: $800-2,000+ per treatment, may be covered by insurance if used for approved depression indication. At-home telehealth lozenges: $400-800 for 6 sessions (cheap but high-risk). Ask your clinic for a clear cost estimate before starting.